CD40LG and influenza: Indeed, a limited number of promising preclinical proof-of-principle studies have been reported for pathogen-targeted therapeutic monoclonal IgM antibodies against influenza,43 severe acute respiratory syndrome coronavirus 2,44 and Neisseria meningitidis.45